A Phase I Trial of ZIO-101 in Hematologic Cancers

NCT00592046 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Leukemia
Chronic Myeloproliferative Disease
Chronic Lymphoproliferative Disease
Multiple Myeloma
Lymphoma
Poor-risk Myelodysplasia (MDS)

Interventions

DRUG: ZIO-101 (Darinaparsin)

Sponsor

Alaunos Therapeutics